Aphios Corporation Granted Japanese Patent for Novel Compositions to Treat Folic Acid Deficiency and Morning Sickness

NORTH READING, Mass.--(BUSINESS WIRE)--Aphios Corporation announced today that it has been granted Japanese Patent No. 7,520,838 for novel compositions to treat folic acid deficiency and morning sickness. The dosage forms have an effective amount of a folic acid, gingerols and shogaols to suppress nausea, relieve gastric distress and promote hematopoiesis.

Pregnancy related nausea and vomiting (PRNV) is the most common medical condition during pregnancy. PRNV affects up to 70% of women during their first trimester, and many in the second and third trimester. The most serious form of PRNV is called Hyperemesis gravidarum (HG) that is reported in up to 10% of pregnant women. PRNV and HG affects women's quality of life and exerts a large economic impact on patients, caregivers and society. There are only a few medications approved by the FDA to treat and manage PRNV and HG.

Folic acid deficiency can also have a significant impact on the health and welfare of newborns, parents, caregivers and society. Folic acid is necessary and critical to fetal development during pregnancy since it promotes DNA synthesis and cell division, affecting hematopoietic cells. In addition to folic acid, a number of medications that include folic acid have been used in the past to treat this deficiency during pregnancy. These supplements are also associated with nausea and upset stomach. There is thus a need to develop improved formulations which do not cause gastric distress and nausea.

According to Dr. Trevor P. Castor, inventor of the patent, “These novel compositions impact high unmet needs to manage pregnancy related nausea and vomiting without synthetic drugs, while improving the health of the fetus and mother with folic acid supplements, managing any resulting gastric distress and improving hemostasis that is accomplished by both gingerols/shogaols and folic acid supplements.”

About Aphios Corporation:

Aphios is an emerging growth, green biotechnology company using earth-friendly supercritical fluids and nanotechnologies to develop enabling technology platforms. Based on these platforms and inspired by nature, we are developing enhanced therapeutics to maintain health, improve quality-of-life and treat chronic diseases including certain cancers and Zindol^® for chemotherapy induced nausea and vomiting (CINV), infectious diseases such as HIV/AIDS, influenza and COVID-19, and CNS disorders such as Alzheimer’s disease and opioid addiction in an environmentally sustainable manner.